Bank of New York Mellon Corp Buys 10,828 Shares of Celcuity Inc. (NASDAQ:CELC)

Bank of New York Mellon Corp grew its stake in Celcuity Inc. (NASDAQ:CELC) by 20.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 64,125 shares of the company’s stock after purchasing an additional 10,828 shares during the period. Bank of New York Mellon Corp owned approximately 0.17% of Celcuity worth $839,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of CELC. Bleakley Financial Group LLC bought a new stake in Celcuity in the fourth quarter worth $146,000. SG Americas Securities LLC raised its stake in shares of Celcuity by 83.2% in the fourth quarter. SG Americas Securities LLC now owns 14,646 shares of the company’s stock valued at $192,000 after acquiring an additional 6,651 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Celcuity in the 3rd quarter worth about $205,000. Quest Partners LLC boosted its stake in shares of Celcuity by 227.6% during the 3rd quarter. Quest Partners LLC now owns 18,962 shares of the company’s stock worth $283,000 after purchasing an additional 13,174 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of Celcuity during the 3rd quarter worth about $307,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC increased their price objective on shares of Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $30.17.

Celcuity Stock Down 3.0 %

Shares of CELC opened at $10.51 on Wednesday. The firm has a fifty day moving average price of $11.24 and a 200-day moving average price of $13.05. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $390.24 million, a P/E ratio of -4.03 and a beta of 0.65. Celcuity Inc. has a 12-month low of $8.53 and a 12-month high of $22.19.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.